Drugs News and Research RSS Feed - Drugs News and Research

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen. [More]
Study shows importance of disclosing physician conflicts of interest in MS ISCTs to potential participants

Study shows importance of disclosing physician conflicts of interest in MS ISCTs to potential participants

If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients. [More]
Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of cancer of the fallopian tube. [More]
Bielefeld University chemists develop copper molecule that could help prevent spread of cancer

Bielefeld University chemists develop copper molecule that could help prevent spread of cancer

Chemists at Bielefeld University have developed a molecule containing copper that binds specifically with DNA and prevents the spread of cancer. First results show that it kills the cancer cells more quickly than cisplatin - a widely used anti-cancer drug that is frequently administered in chemotherapy. [More]
U-M researchers reveal key role of two enzymes that help the body to remove cholesterol, other lipids

U-M researchers reveal key role of two enzymes that help the body to remove cholesterol, other lipids

With the aid of X-ray crystallography, researchers at the University of Michigan have revealed the structures of two closely related enzymes that play essential roles in the body's ability to metabolize excess lipids, including cholesterol. [More]
Study explores use of antipsychotic medications among pediatric patients

Study explores use of antipsychotic medications among pediatric patients

More kids nationwide are taking medications designed to treat such mental illnesses as schizophrenia and bipolar disorder, and pediatricians and psychiatrists at the University of Vermont want to know why. [More]
Study debunks false reports surrounding risk of hormone therapy

Study debunks false reports surrounding risk of hormone therapy

For over a decade, hormone therapy (HT) has been a hot topic in medicine. Unfortunately, women are still confused and concerned about using HT after two federally-funded studies linked HT to potentially serious health risks. [More]
Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets. [More]
Physicians urge households to add 'clean my medicine cabinet' to Spring cleaning chores list

Physicians urge households to add 'clean my medicine cabinet' to Spring cleaning chores list

After marijuana and alcohol, the most commonly abused drugs by those over the age of 14 are prescription and over-the-counter medications. [More]
Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics, Inc. today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed. [More]
WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355). [More]
CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online in JAMA Oncology. [More]

Researchers investigate efficiency of drug research and development

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could be responsible. [More]
Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

A paper published today, "Financing translation: Analysis of the NCATS rare-diseases portfolio" in Science Translational Medicine, demonstrates the potential of a new financing technique to reduce the risk associated with investing in the treatment of new diseases and potentially unlock new levels of funding for developing so-called "orphan" drugs. [More]
Rare Disease Day 2015 raises awareness of challenges faced by rare cancer patients

Rare Disease Day 2015 raises awareness of challenges faced by rare cancer patients

Within the "umbrella" of rare diseases, rare cancer patients confront particular problems. Most rare diseases have an identified genetic origin. In contrast, rare cancers are mainly acquired diseases. [More]
Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Bionomics Limited is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando, Florida. The data will be presented by Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center in California in his poster presentation. [More]
Researchers successfully convert adult human skin cells into neurons that control appetite

Researchers successfully convert adult human skin cells into neurons that control appetite

Researchers have for the first time successfully converted adult human skin cells into neurons of the type that regulate appetite, providing a patient-specific model for studying the neurophysiology of weight control and testing new therapies for obesity. [More]
Patients who undergo chemo before breast cancer operation more likely to opt for lumpectomy

Patients who undergo chemo before breast cancer operation more likely to opt for lumpectomy

Patients with larger malignant tumors of the breast who undergo chemotherapy before a breast cancer operation are more likely to opt for a breast-preserving procedure and forgo a mastectomy (surgical removal of the breast), according to a new study published online as an "article in press" in the Journal of the American College of Surgeons. [More]
Neuroprotective compounds can limit damage to the brain during ischemic stroke

Neuroprotective compounds can limit damage to the brain during ischemic stroke

In the 1990s, neuroscientists identified a class of drugs that showed promise in the area of stroke. NMDA receptor antagonists could limit damage to the brain in animal models of stroke. But one problem complicated testing the drugs in a clinical setting: the side effects included disorientation and hallucinations. [More]
New pharmacological compounds block nerve cell damage in mouse models of MS

New pharmacological compounds block nerve cell damage in mouse models of MS

A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience. [More]